Javascript is disabled

Javascript seems to be disabled. This will break some core site features. Please enable javascript or revisit this site from another device.



Descriptions of program sessions at NETCM9 

Wednesday May 22nd
Tivoli Congress Hall

The transition from pandemic to endemic transmission
Pandemic, epidemic and endemic transmission are constructions established by epidemiologist to describe different scenarios of disease transmission. But the transition between these different stages is gradual, and can best be understood when we reflect on past outbreaks of diseases. My talk will reflect on historical pandemics to learn about the current transition from pandemic to endemic transmission of COVID-19.

Thursday May 23rd
Tivoli Congress Hall

Theatre of death
Mr. Larsen has written several acclaimed books on the history of medicine. He will take the audience through a brief, illustrated narrative of surgery, medicine and disease from the Middle Ages and forward until the scientific breakthrough at the end of the 19th century.

Climate change and travel
It is unequivocal that human influence has warmed the atmosphere, where widespread and rapid changes have occurred. The scale of recent changes across the climate system as a whole – and the present state of many aspects of the climate system – are unprecedented over many centuries to many thousands of years. Human-induced climate change is already affecting many weather and climate extremes in every region across the globe.

Climate change and arboviruses
This presentation will highlight the impact of climate change on arbovirus transmission and provide insights into the epidemiology of arbovirus outbreaks in temperate climates, with an emphasis on Aedes-borne infections in Europe.

Understanding emerging pathogens - what did we learn about Mpox?
An unforeseen global outbreak of Mpox occurred in 2022, with localised transmission primarily in GBMSM. To date, cases of Mpox remain high in countries such as Nigeria and DRC, in addition to new outbreaks in South-East Asia and sustained cases within the UK, EU, and USA. Here we will consider the implications of the future trajectory of Mpox and what this means for future pathogens and outbreaks.


Immunological aspects of co-administration of vaccines in adulthood
In this engaging journey, we will explore the latest findings, listen to the fascinating stories, and share valuable lessons learned from previous studies on the immunological aspects of vaccine coadministration in adulthood.

Chlamydia trachomatis vaccine development
The first chlamydia vaccine candidate has now been tested in two phase clinical I trials with very encouraging safety and immunogenicity data. I will discuss what it will take to continue the clinical development of a chlamydia vaccine and what future trial setups could look like.


Enteric fevers
Enteric fever caused by Salmonella (para) Typhi bacteria is in many parts of the world still endemic and remains a major burden for people living in endemic areas as well as for travelers. In this overview new literature and current insights on the pathogenesis, epidemiology, and (preventive) treatment strategies for enteric fever will be discussed.

Ricketssioses in travelers
International tourism including in rural and remote places increasingly exposes travelers to tick bite and tick-borne diseases. In this lecture, the main tick-borne rickettsioses reported in travelers in the past years will be reviewed, including emerging diseases, as well as diagnosis and therapeutic issues.

Risk Assessment in travellers
An interactive session focusing on:
-the art of information gathering,  
-identifying  the individual traveller’s health risks during their trip and      
-how to manage all this effectively within the time constraints of a clinic appointment.

Special risk groips: Backpackers, VFR travelers
The presentation will discuss the specific risk factors for backpackers and VFR travelers, along with practical advice. It draws from both literature and personal experiences as a travel health advice nurse.

Yellow fever training program England, Wales and Northern Ireland
In England, Wales and Northern Ireland, Yellow Fever Vaccination Centres (YFVC) are required to complete NaTHNaC yellow fever training as part of the designation process. This presentation will describe the current yellow fever course and the training requirements for a YFVC to remain designated.

Malaria chemoprophylaxis in the travel clinics
Various travelcases; what chemoprophylaxis advice is given in The Netherlands and what should you advice? Overview & quiz.

How to communicate risk in travelers
Risk communication is an open two way exchange of information and opinion about harms and benefits of potential activities, with the aim of improving the understanding of risk and of promoting better decisions about risk management.  This presentation will aim to identify the more effective methods from the risk communication literature and apply this concept to the travel medicine consultation whilst also considering the challenges this presents.

Friday May 24th
Tivoli Congress Hall

Working in warzones
Dr McCarthy will discuss the risks, preparations and challenges for those working in areas of conflict. Taking care of individuals doing this kind of work extends beyond the routine travel medicine consultation, and requires special care before, during and after time in the conflict zone.

Natural disasters
The presentation will through examples from the medical humanitarian work of MSF, show how health interventions are managed in situations of natural disasters, which diseases and epidemics are present and which consequences it has for the population.

Recreational SCUBA-diving is a frequent part of travelling. An international medical certification is presented and essential safety advice is given.

A statement of fit-for-travel may have few legal implications, but it can be very consequential for the traveller. Since screening is simple, then there is no excuse not to take it seriously.


Sustainable travel in Arctic areas
Increasing tourist visitation across the Arctic regions has intensified pressures on often small and remote communities in terms of infrastructure, destination development and good governance. This talk presents examples of growing impacts, risks and concerns in current Arctic tourism and points to viable pathways towards a more sustainable development in Arctic tourism.

Coldexposure injuries
How to prevent and treat cold weather injuries.

Clinical decision supprt systems to increase the decetion of infections and other conditions in migrants
This talk will discuss screening programmes targeting migrant populations, in particular those that use an individualized risk-assessment. In addition, we will discuss how the development of clinical decision support systems using structured and unstructured data from electronic patients records, could identify migrants coming from areas endemic at risk for certain imported diseases and to facilitate the early detection of those conditions in order to prevent potential complications.

When to screen and what to screen for in migrants and refugees
Delving into the complexities of health screening for refugees and migrants, this conference lecture explores the diverse health risks and logistical challenges inherent in providing culturally competent care. It highlights the importance of incorporating knowledge of travel medicine into a meaningful context for vulnerable populations, emphasizing evidence-based screening programs and collaborative strategies. Through this approach, the lecture aims to inspire innovative solutions for ensuring long-term healthcare integration and addressing the unique needs of displaced populations.


Yellow fever vaccination in non-hiv infected immune compromised traveler and beyond
A single dose of yellow fever vaccination provides lifelong protection in travellers. However, in certain populations booster doses might still be required.

Yellow fever vaccination of people living with HIV: duration of protection and need for a booster
PLWHIV probably need a specific vaccination program against YF but there is not enough rational basis for its development. We have been able to put together several elements to develop a proposal for a specific vaccination program against YF for PLWHIV, even if several questions remain to be studied in the future.